Brief: Immunotech Biopharm Announces Clinical Trial Approval For AT19 Injection
19/02/2024 14:29
Feb 19 (Reuters) - Immunotech Biopharm Ltd 6978.HK :
* CLINICAL TRIAL APPROVAL FOR AT19 INJECTION
* APPROVAL FROM CENTRE FOR DRUG EVALUATION OF NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION
Source text for Eikon: ID:n11071418-1
Further company coverage: 6978.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunotech Biopharm
See all newsBrief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
Brief: Trading In Shares Of Immunotech Biopharm Will Be Halted At 1:00 PM On April 28, HKEX Says
Brief: Immunotech Biopharm Posts Loss And Total Comprehensive Expense For Year Attributable Rmb230.8 Million
Brief: Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN